Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). (Q33398716)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). |
scientific article |
Statements
1 reference
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). (English)
1 reference
Hagop M Kantarjian
1 reference
Michele Baccarani
1 reference
Jorge E Cortes
1 reference
Tadeusz Robak
1 reference
M Brigid Bradley-Garelik
1 reference
Carolina Pavlovsky
1 reference
Jorge H Milone
1 reference
Edo Vellenga
1 reference
Neil P Shah
1 reference
Mohan B Agarwal
1 reference
MarÃa Soledad Undurraga
1 reference
Jianxiang Wang
1 reference
Juan Julio Kassack Ipiña
1 reference
Dong-Wook Kim
1 reference
Michinori Ogura
1 reference
Christian Junghanss
1 reference
Franck E Nicolini
1 reference
Jan Van Droogenbroeck
1 reference
Chao Zhu
1 reference
9 December 2011
1 reference
1 reference
Identifiers
1 reference